Athersys (ATHX) +8.9% premarket after announcing its met with the FDA to discuss results of its...

|By:, SA News Editor

Athersys (ATHX) +8.9% premarket after announcing its met with the FDA to discuss results of its recent clinical trial involving the administration of its MultiStem treatment for patients with leukemia or other conditions that place them at risk of graft vs. host disease.